Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT04968548
Official study title

Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening

Study summary

This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedBlood collection

The study team can explain what participation involves.

Who it may be forEarly-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 30, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?31 U.S. locations

Locations may change over time.

Who runs it?Nucleix Ltd.

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Nucleix Ltd.
Interventions being studied
Procedure: Blood collection
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Early-stage or resectable→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Cases:
  • Current or past smokers, with at least 20 pack-years
  • Subjects with either A high suspicion for lung cancer, with planned surgery to establish a definitive diagnosis within 60 days after date of blood collection OR treatment naive lung cancer patients
Reasons someone may not be able to joinExclusion criteria
  • Cases:
  • Known diagnosis or treatment of any previous cancer, including lung cancer, in the past 5 years, except for fully resected non-melanoma skin cancer or fully-resected carcinoma in situ of the cervix
  • Current lung cancer is known to be stage III or IV by pathology. Inclusion Criteria - Screening: \- Current or past smokers, with at least 20 pack-years, undergoing LDCT for lung cancer screening

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Scripps Memorial HospitalEncinitas, California
  • Centura HealthLakewood, Colorado
  • VA Connecticut Healthcare SystemWest Haven, Connecticut
  • Orlando Health, Inc.Orlando, Florida
  • Sarasota Memorial HospitalSarasota, Florida
  • St. Elizabeth Edgewood HospitalEdgewood, Kentucky
  • Norton Cancer InstituteLouisville, Kentucky
  • Owensboro HealthOwensboro, Kentucky
  • Johns Hopkins Medical CenterBaltimore, Maryland
  • Lahey Hospital and Medical CenterBurlington, Massachusetts
  • University of Minnesota HealthMinneapolis, Minnesota
  • Harry S. Truman Memorial Veterans' HospitalColumbia, Missouri

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 30, 2026. Always confirm current availability with the study team.

View original record ↗